ATR (Ataxia Telangiectasia and Rad3-related) Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

ATR (Ataxia Telangiectasia and Rad3-related) Inhibitors are a class of molecules bearing promising therapeutic properties that have gained attention in cancer research and beyond. ATR is a protein kinase involved in the cellular DNA damage response and plays a crucial role in maintaining genomic stability. ATR Inhibitors target this kinase and have shown the potential to enhance the effectiveness of cancer treatments by sensitizing tumor cells to DNA-damaging agents.

ATR Inhibitors act on the ATR kinase, a key component of the DNA damage response pathway, responsible for detecting and repairing DNA damage. Upon administration, ATR Inhibitors block the activity of the ATR kinase, disrupting the DNA damage response and causing a buildup of DNA damage. This makes cancer cells more vulnerable to treatments that induce DNA damage, such as chemotherapy and radiation therapy. ATR Inhibitors are primarily used in cancer therapy, particularly in combination with DNA-damaging treatments, to enhance their efficacy against various cancer types. These inhibitors have shown promise in clinical trials for treating solid tumors, including ovarian cancer, lung cancer, and head and neck cancers. According to the World Health Organization (WHO), ovarian cancer is a significant global health concern, the eighth most common cancer in women worldwide. ATR Inhibitors offer a potential new approach to improving outcomes for patients with this challenging disease. Extensive research is being conducted globally to discover new and novel molecules to be used, like ceralasertib which is used for treating many indications like Leukemia. The development and launch of new products will thus increase the market's revenue in the forecasted years.

Several of these inhibitors are on the market, while many are in ongoing clinical trials. 14 companies have various products in their pipelines, with 12 products in different stages of clinical trials – 1 in Phase 3, 9 in Phase 2, and 2 in Phase 1 of the clinical trials.

Drugs in the Pipeline of ATR Inhibitors

  • Ceralasertib (AZD6738)
  • Berzosertib (M6620)
  • Elimusertib (BAY 1895344)
  • Tuvusertib (M1774)
  • Camonsertib (RP-3500)
  • Gartisertib (M4344)
  • ART0380
  • ATG-018
  • ATRN-119
  • HRS2398
  • IMP9064
  • SC0245

Clinical Activity and Developments of ATR Inhibitors

As of July 2023, various companies have approximately 12 products for 3 diseases. For these diseases, 83 trials are being conducted by players globally. For instance,

  • AstraZeneca is conducting a Phase 3 clinical study of Ceralasertib plus Durvalumab vs. Docetaxel in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer without actionable genomic alterations and whose disease has progressed on or after prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy that is expected to complete by May 2025.
  • National Cancer Institute is conducting a Phase 2 clinical of M6620 (VX-970) in combination with Gemcitabine vs. Gemcitabine alone in subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer that was estimated to complete by March 2023.
  • National Cancer Institute is conducting a Phase 2 clinical trial of Topotecan plus M6620 (VX-970, Berzosertib) vs. Topotecan alone in patients with Relapsed Small-Cell Lung Cancer that is expected to complete by September 2023.

Molecule name

Number of studies

ceralasertib (AZD6738)


berzosertib (M6620)


elimusertib (BAY 1895344)


tuvusertib (M1774)


camonsertib (RP-3500)


Target Indication Analysis of ATR Inhibitors

ATR Inhibitors have emerged as a versatile class of therapeutic agents with numerous indications, some of which hold particular promise in medical research. Among these indications, their most significant use lies in cancer treatment. ATR Inhibitors have shown efficacy in enhancing the effects of DNA-damaging therapies, making them valuable candidates for various cancer types. Notably, they find frequent use in ovarian cancer, where ATR Inhibitors sensitize tumor cells to chemotherapy, potentially improving treatment outcomes. Additionally, they hold potential in lung cancer, head and neck cancers, and colorectal cancer, where their ability to disrupt the DNA damage response pathway offers new possibilities for treatment. Furthermore, ATR Inhibitors have demonstrated promise in combination with immunotherapy, enhancing the immune response against cancer cells. Beyond oncology, these inhibitors show potential in certain genetic disorders, such as ataxia-telangiectasia and Fanconi anemia, where they may help counteract the consequences of defective DNA repair mechanisms. As research advances, ATR Inhibitors continue to unveil their therapeutic potential across various medical fields.

Frequently Asked Questions

Currently, no ATR Inhibitor has been approved by the FDA.

These are used for treating diseases of Ovarian cancer, Acute Lymphoid LEUKEMIA, Lymphomas, Head and Neck Cancer, and others.

AstraZeneca, EMD Serono Inc, Bayer AG, Roche, and Artios Pharma Ltd are some of the major market players for ATR Inhibitors.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and rising incidence of various types of cancers like Acute Lymphoid Leukemia, Ovarian cancer, and others are the key opportunities for ATR Inhibitors in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • AstraZeneca
  • EMD Serono Inc
  • Bayer AG
  • Roche
  • Artios Pharma Ltd
  • Antengene Corporation
  • Aprea Therapeutics Inc.
  • Jiangsu Hengrui Pharma
  • Impact Therapeutics
  • Shijiazhuang Sagacity New Drug Development Co., Ltd.
  • Wuxi Biocity Biopharmaceutics

Adjacent Markets